Study Summary
One arm, open label study to assess the clinical use of Investigational Medicinal Product FCTX-CL19-1 (scientific name: Tarcidomgen Kimleucel) containing autologous anti-CD19 CAR T cells with a preliminary determination of the safety of intravenous IMP administration in patients diagnosed with refractory and relapsed CD19 + B cell neoplasms.
Want to learn more about this trial?
Request More InfoInterventions
FCTX-CL19-1 (Tarcidomgen Kimleucel)BIOLOGICAL
It will be administered only by Investigators during hospitalization. Each patient will receive one administration of IMP on Day 0:
* administration route - intravenous
* cell dose: 0,2 x 106 -2 x 106 CAR T cells per kilogram of patient body weight
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego - Centralny Szpital Kliniczny | Warsaw | Ul. Banacha 1a | Poland |
| Uniwersyteckie Centrum Kliniczne Gdańskiego Uniwersytetu Medycznego - Katedra i Klinika Hematologii i Transplantologii | Gdansk | Ul. Smoluchowskiego 17 | Poland |